A study of 128 women linked oral minoxidil to less hair-loss progression. We explain the regrowth findings, limitations, and clinical relevance.
On October 29, 2026, a study published online in the Journal of the American Academy of Dermatology reported less hair-loss progression among women receiving low-dose oral minoxidil than among those using topical minoxidil. According to Medscape’s coverage, both groups experienced similar improvements in their hair-thinning scores.
The distinction is important: improving the appearance of thinning and limiting further progression are different treatment goals. This study draws attention to the second goal. Its most notable finding was not a statistically significant advantage in regrowth scores but a difference in how often worsening was recorded.
According to Medscape, the retrospective cohort included 128 women with female pattern hair loss at one academic dermatology practice. Of these women, 71 received low-dose oral minoxidil and 57 received 5% topical minoxidil foam.
The groups had similar mean ages: 55.7 years in the oral-treatment group and 55.8 years in the topical-treatment group. This gives the comparison particular relevance to discussions about treatment during midlife.
Two blinded raters assessed standardized scalp photographs using Sinclair scores in quarter-grade increments. A board-certified dermatologist reviewed the scores and resolved disagreements. The researchers also recorded whether hair loss progressed or stabilized.
These measures address related but distinct questions. A change in a photograph-based score describes improvement in the assessed thinning. Progression and stabilization describe whether the condition worsened or remained stable during observation.
Medscape reported that mean Sinclair scores improved by 0.30 points with oral minoxidil and 0.20 points with topical treatment. The adjusted difference between groups was not statistically significant (P = .24).
The study also reported that oral treatment met its prespecified noninferiority criterion (P = .014). Read together, these findings support the authors’ description of comparable regrowth outcomes. They do not support a headline claiming significantly greater regrowth with oral treatment.
The score changes are worth keeping in their original form. A change in a thinning score should not be rewritten as a percentage increase in hair density or a particular amount of visible regrowth. Those would be different measurements from the ones reported here.
The clearer separation appeared in the progression results:
After adjustment for potential confounders, oral treatment remained associated with lower odds of progression. Medscape reported an adjusted odds ratio of 0.16 (P = .021).
Stabilization rates were similar: 34% with oral treatment and 33% with topical treatment. The combination of similar average score improvements and different progression rates is the central finding of this comparison.
The authors suggested that oral treatment “may provide an advantage” when preventing long-term progression is the patient’s primary goal. That interpretation came from the study authors rather than an independent expert assessment.
The study was retrospective and came from a single center. It establishes an association rather than proving that the oral route caused less progression. Statistical adjustment addresses measured differences between groups but cannot rule out residual confounding or establish how the findings will translate to other settings.
Follow-up also differed. The oral-treatment group had a mean follow-up of 11.0 months compared with 15.8 months for the topical-treatment group. That unequal observation period complicates the comparison of progression over time.
The researchers lacked adherence data and did not specify a washout period. These gaps leave uncertainty about treatment use and the possible influence of prior treatment. They matter when interpreting a comparison between medication taken orally and medication applied to the scalp.
Comparative safety remains a separate unanswered question. Medscape’s report does not provide comparative adverse-event results or specify the oral dose. The reported hair outcomes therefore do not establish that oral treatment is safer or provide a basis for recommending a regimen.
This was an observational comparison in clinical practice rather than a controlled trial. Its results should be understood as outcomes recorded in this particular cohort, not as a prediction of what an individual woman will experience.
The useful practical message is to make the treatment goal explicit. A discussion about improving visible thinning is not quite the same as a discussion about maintaining the current appearance over time. This study gives clinicians and patients a reason to consider both outcomes separately.
The American Academy of Dermatology (AAD) identifies minoxidil as its most-recommended treatment for female pattern hair loss. Its patient guidance states that 2% and 5% topical minoxidil products are approved for this condition in the United States. That established role provides context for the topical treatment used in the comparison.
The AAD also explains that topical minoxidil may take six to 12 months to assess. It can cause scalp irritation or temporary increased shedding during the first two to eight weeks. These are relevant considerations for a clinical discussion about expectations and sustained use, not reasons to assume that one route is automatically preferable.
For an individual decision, the conversation belongs with a qualified clinician. Useful questions include:
Younell’s framework for comparing treatment choices offers a broader way to organize those questions. For readers seeking context on the assessment itself, our guide to evaluating possible causes of hair loss keeps the diagnosis in view.
The purpose is not to choose a tablet on the strength of a headline. It is to bring a more precise question to the consultation: which outcomes matter most, and how does the available evidence inform that discussion?
The next research question is whether the progression difference persists in comparisons with similar follow-up and better information about treatment use. Comparative adverse-event reporting would also help place the hair outcomes alongside safety outcomes.
For now, the study adds a specific observation to the evidence: similar improvements in Sinclair scores accompanied by less frequently recorded progression in the oral-treatment group. It strengthens the case for studying prevention of further thinning as a distinct outcome, alongside visible regrowth.
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
